Fig. 3
From: EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells
Co-administration of EZH2 inhibitors with gefitinib significantly suppresses lung cancer cell growth in vitro. Cells were subjected to control treatment (NC), GSK343 (11 μmol/L), DZNep (10 μmol/L), gefitinib (12 μmol/L), G + g (11 μmol/L GSK343 + 12 μmol/L gefitinib), or D + g (10 μmol/L DZNep + 12 μmol/L gefitinib) for 48 h. a Cell viabilities of A549 and H1299 cells were tested by CCK-8 assay. b The effects of different drug treatments on cell proliferation of A549 cells was measured by colony formation assay. c-d The effects of GSK343, DZNep, and gefitinib on cell proliferation of A549 and H1299 cells were evaluated by EDU assay.** P < 0.01 vs. the gefitinib alone-treated group. e-f Cell cycle of A549 and H1299 cells were analyzed by flow cytometry analysis. Data are presented as mean ± standard deviation